- Home
- PRHI vs ABP Comparison
PRHI vs ABP Comparison
Compare PRHI & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | ABP |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 12.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRHI | ABP |
|---|---|---|
| Price | $0.70 | $4.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 93.5K | 14.3K |
| Earning Date | 11-12-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,664,000.00 | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $0.42 | $3.78 |
| 52 Week High | $2.83 | $47.10 |
Technical Indicators
Market Signals| Indicator | PRHI | ABP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.68 |
| Support Level | N/A | $3.98 |
| Resistance Level | N/A | $5.09 |
| Average True Range (ATR) | 0.00 | 0.38 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 29.32 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.